INNOVATE
Therapeutic Antibodies
Therapeutic Antibodies project is about developing the use of antibodies as a bioactive molecules by improving their structure, the choice of therapeutic targets and reducing the cost of research and development as well as time-to-market.
This project builds on strong technological skills and knowledge present in Rhône-Alpes region in terms of structural and analytical study of antibody-antigen complex.
The goal is to develop a real technology network to cover the entire value chain of production of a therapeutic antibody.
Technological partners:
European Synchrotron Radiation
Facility, Grenoble
Elspeth GORDON
Industrial Liaison Scientist
Institut de Biologie
Structurale, Grenoble
Anne-Marie DI GUILMI
Researcher
Contact:
Nicolas GROUX
Project manager Therapeutic Antibodies
Phone.: +33 (0)4 37 70 10 12
Email : nicolas.groux@lyonbiopole.com
Lyonbiopole
Bâtiment Domilyon
321, avenue Jean Jaurès
69007 LYON
They speak about...
« Innovations by biotech firms still take too long to reach major pharmaceutical companies, despite the growing needs of industrial firms and their interest in these breakthroughs in the area of personalized treatment. One of the main reasons is that start ups lack networks and visibility in the eyes of these large industrial groups. These two complementary players thus need a catalyst to create meetings, pass on information and contact one another. This is what World Competitive Clusters like Lyonbiopole do. ImmunID has benefited from this effective support, and we have had excellent results in 2008 and 2009, signing contracts with several firms which are leaders in their field, such as Sanofi Pasteur. In the end, Lyonbiopole is an organization which plays an active role in setting up and giving impetus to future high potential R&D projects in the health sphere. »
Nicolas Pasqual
ImmunID Technologies - Ph.D. CEO